Skip to content

G&A at other companies

IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$19.38M+43.5%
CG Oncology logo
CG OncologyCGON
$20.78M+40.5%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$11.37M+81.5%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$5.71M-5.2%
Immunome logo
ImmunomeIMNM
$12.95M+21.1%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$29M+3.6%

Other financials

Income statement

See full
Operating income-$34.9M-20.1%
Net income-$33.7M-22.6%
EPS (diluted)-$0.50+9.1%

Balance sheet

See full
Cash & equivalents$84.8M+122%
Total debt$17.0M-7.9%
Total equity$107.2M-16.2%
Total assets$137.7M-11.4%

Cash flow

See full
Operating cash flow-$29.9M-28.0%
CapEx$102.0K-45.5%
Free cash flow-$30.0M-27.4%

Valuation

See full
Market cap$709.23M+89.4%
Enterprise value$641.43M+80.8%

Returns & leverage

See full
Return on equity-95.6%+222pp
Debt / equity0.2×0.0×
Current ratio7.1×-4.0×

Where this comes from

Reported directly by Aura Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Aura Biosciences, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aura Biosciences, Inc.'s g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aura Biosciences, Inc.'s G&A?
Aura Biosciences, Inc. (AURA) reported G&A of $6.91M in Q1 2026.
How has Aura Biosciences, Inc.'s G&A changed year-over-year?
Aura Biosciences, Inc.'s G&A increased by 21.3% year-over-year, from $5.69M to $6.91M.
What is the long-term trend for Aura Biosciences, Inc.'s G&A?
Over 4 years (2021 to 2025), Aura Biosciences, Inc.'s G&A has grown at a 22.2% compound annual growth rate (CAGR), from $10.09M to $22.49M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.